Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
What they do
Pharos iBio develops an AI-driven drug discovery platform, Chemiverse, which manages over 200 million biological data points. Biotechnology companies and clinical researchers use the platform to predict clinical toxicity, discover novel indications, and optimize target compounds.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Public
- Headquarters
- Anyang, South Korea
- Region
- Asia-Pacific
- Founded
- 2014
- Total funding
- $20M raised
Notable investors: Korea Investment Partners, DSC Investment, KDB Bank.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA